Thursday, August 08, 2019 6:34:48 AM
________________________________________________________________________________________________________
The weaker the signal the higher the n or trial participants needs to be to show Stat Sig.
https://investorshub.advfn.com/boards/read_msg.aspx?mmessage_id=150305920
Novel trials designs such as “basket,” “umbrella,” etc
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150179911
Procedure and implications of post trial access to drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149179546
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149180303
Sponsor has an obligation to monitor the trial as well as ensuring the Investigator is following protocol
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149408725
When to Stop a Clinical Trial Early for Benefit
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149768695
This could speed up and simplify and reduce cost of “precision enrollment” screening time:(from biostockclub)
https://neurosciencenews.com/artificial-intelligence-alzheimers-13097/
“The Future of Drug Trials Is Better Data and Continuous Monitoring” (from kevli33)
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring
Multi-regional clinical trials and global drug development - 2016 changes in trial technique:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099281
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099929
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149100322
As of January Anavex has a QPPV- needed for EU approval. (from TTTav66)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146643593
Qualified Person Responsible For Pharmacovigilance - Wikipedia
https://en.wikipedia.org/wiki/Qualified_Person_Responsible_For_Pharmacovigilance
Expedited approval in Asia
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145657979
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145658475
An example of provincial level drug approval in Canada: (from nidan7500)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148351451
Japan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770129
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770231
Japanese accelerated approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148389943
Reasons why it's good to be running trials in Australia...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033379
Patient Centricity And Social Media Are Changing Patient Recruitment (from Kevli33)
https://www.clinicalleader.com/doc/patient-centricity-and-social-media-are-changing-patient-recruitment-0001
PDD/AD trials in Australia/Spain-Australia and EU can exchange scientific information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148650906
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148655115
A Brief History of Placebos and Clinical Trials in Psychiatry
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148139761
indialong cites FDA gidance concerning need for placebo in studies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154841
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154913
TempePhil gives us links to all three Anavex trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146017758
TTTav66 analysis of trial recruitment and enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420519
Worst case enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146083304
2-73 preclinical improvement of learning and behavior:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390935
A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings (from nidan7500)
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
Will Canada give Conditional Approval if Australia does?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221699
How enrollment works:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144955802
Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889
A "sobering read" on precision medicine from Investor2014
https://blogs.sciencemag.org/pipeline/archives/2019/01/31/precision-medicine-real-soon-now
Trial interpretation - What’s in a p value? - a significant read! (from Investor2014)
http://www.evaluate.com/vantage/articles/analysis/vantage-views/whats-p-value
On dosage of 2-73 and P values:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639
Infantile Spasms Market analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347329
Rett Syndrome Market Analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347491
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM